KDR and neoplasm: For instance, sorafenib in advanced HCC targets kinases such as rapidly accelerated fibrosarcoma (RAF), VEGFR, and platelet-derived growth factor receptor (PDGFR) to inhibit tumor growth and angiogenesis, and induces an improvement in OS from 7.9 to 10.7 months compared to placebo [136].